THE SENATE THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII

S.B. NO. 1454

JAN 2 5 2023

A BILL FOR AN ACT

RELATING TO PSILOCYBIN.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

SECTION 1. The legislature finds that there is heightened awareness of the detrimental effects of untreated and maltreated mental health in our population. With a shortage of mental health professionals and appropriate mental health care, the State must actively consider innovative and effective treatment options to address this pressing need.

7 The legislature further finds that psilocybin has been 8 found to be very effective in treating a variety of mental health conditions, including but not limited to post-traumatic 9 10 stress disorder, depression, anxiety, and end-of-life 11 psychological distress. As a result, the United States Food and 12 Drug Administration has designated treatment that uses 13 psilocybin in a therapeutic manner for treatment resistant 14 depression as a "breakthrough therapy".

15 The legislature also finds that at least two states, Oregon 16 and Colorado, have found that legalizing medicinal psilocybin is



S.B. NO. 1454

a valuable tool in dealing with various mental health
 conditions.
 Accordingly, the purpose of this Act is to establish the
 therapeutic psilocybin working group to:
 (1) Examine the medicinal and therapeutic effects of
 psilocybin or psilocybin-based products vis-à-vis

7 mental health including post-traumatic stress
8 disorder, depression, anxiety, and end-of-life
9 psychological distress;

10 (2) Examine the effectiveness of medicinal and therapeutic
11 uses of psilocybin or psilocybin-based products in
12 treating mental health in the two states that have
13 legalized medicinal psilocybin, Oregon and Colorado;
14 and

15 (3) To determine and develop a long-term strategic plan to 16 ensure the safe availability and accessibility of 17 affordable, therapeutic psilocybin or psilocybin-based 18 products for adults twenty-one years of age or older. 19 SECTION 2. (a) There is established a therapeutic 20 psilocybin working group within the department of health for 21 administrative purposes.

2023-1082 SB SMA.docx

S.B. NO. 1454

1 (b) The working group shall:

- 2 (1) Examine federal, state, and local laws, regulations,
 3 administrative rules, and procedures regarding the
 4 therapeutic use of psilocybin;
- 5 (2) Examine medical, psychological, and scientific
 6 studies, research, and other information relating to
 7 the efficacy and safety of psilocybin or psilocybin8 based products in treating mental health disorders,
 9 including post-traumatic stress disorder, depression,
 10 anxiety, and end-of-life psychological distress;
- 11 (3) Examine existing laws, requirements, and guidelines in 12 jurisdictions in which psilocybin or psilocybin-based 13 products is legally used to treat mental health 14 conditions; and
- 15 (4) If appropriate, determine and develop a long-term
 16 strategic plan to ensure the safe availability and
 17 accessibility of affordable, therapeutic psilocybin or
 18 psilocybin-based products for adults twenty-one years
 19 of age or older.

20 (c) The working group shall consist of the following21 individuals:



Page 4

S.B. NO. 1454

1	(1)	The director of health, or the director's respective
2		designee, who shall serve as chairperson of the
3		working group;
4	(2)	The attorney general, or the attorney general's
5		respective designee;
6	(3)	The dean of the John A. Burns school of medicine at
7		the University of Hawaii at Manoa, or the dean's
8		respective designee;
9	(4)	The chairpersons of the health and the judiciary
10		standing committees within the senate and house of
11		representatives, or the respective designees of the
12		health and the judiciary standing committees within
13		the senate and house of representatives as appointed
14		by the senate president and the speaker of the house
15		of representatives;
16	(5)	The chairperson of the Hawaii state council on mental
17		health, or the chairperson's respective designee;
18	(6)	A physician duly licensed pursuant to chapter 453,
19		Hawaii Revised Statutes, or an advanced practice
20		registered nurse who is authorized to prescribe
21		psychotrophic medication and is duly licensed pursuant





1		to chapter 457, Hawaii Revised Statutes, as invited by	
2		the chairperson of the working group;	
3	(7)	A psychiatrist duly licensed pursuant to chapter 453,	
4		Hawaii Revised Statutes, as invited by the chairperson	
5		of the working group; and	
6	(8)	Other interested parties with relevant experience and	
7		expertise, as invited by the chairperson of the	
8		working group.	
9	(d)	The members of the working group shall serve without	
10	compensation but shall be reimbursed for expenses, including		
11	travel ex	penses, necessary for the performance of their duties.	
12	No member	of the working group shall be subject to chapter 84,	
13	Hawaii Re	vised Statutes, solely because of the member's	
14	participation in the working group.		
15	(e)	The working group shall submit a report of its	
16	findings	and recommendations, including any proposed	
17	legislati	on, to the legislature no later than twenty days prior	
18	to the co	nvening of the regular session of 2024.	
19	(f)	The working group shall be dissolved on June 30, 2025.	



Page 5

.

S.B. NO. 1454

1 SECTION 3. This Act shall take effect upon its approval.

2

INTRODUCED BY:

1 1. 111 -/U

BY REQUEST

By Beguesi



S.B. NO. 1454

Report Title:

Psilocybin; Department of Health; Working Group; Report

Description:

Establishes the Therapeutic Psilocybin Working Group.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

